{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-057825","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.876999+00:00","generated_at":"2026-06-15T08:01:14.883022+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Innoviva Q1 net income $34.9M ($0.51 EPS); GSK royalties $60.3M","bullets":["Net income $34.9M ($0.51 basic EPS) vs $15.8M ($0.23) YoY.","GSK royalty revenue $60.3M, down from $93.5M YoY due to TRELEGY royalty sale in July 2022.","Net product sales & license revenue $19.5M ($9M GIAPREZA, $2.5M XERAVA, $8M milestone from China XERAVA approval).","Repurchased $40.3M of common stock (3.4M shares); paid off $96.2M of 2023 convertible notes.","FDA advisory committee unanimously voted 12-0 for sulbactam-durlobactam; PDUFA target date May 29, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-057825","json":"https://secwatch.observer/filing/0001104659-23-057825.json","markdown":"https://secwatch.observer/filing/0001104659-23-057825.md","text":"https://secwatch.observer/filing/0001104659-23-057825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923057825/0001104659-23-057825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923057825/tm2315160d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:01:14.883022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09258d9c8bc5565c1a08a44be8acea44dfbc8b4d","claim":"Innoviva, Inc. reported first quarter ended March 31, 2023 results: net income Net income was $34.9 million, EPS $0.51 basic per share.","evidence_excerpt":"Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923057825/0001104659-23-057825-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"Net income was $34.9 million"},{"label":"EPS","value":"$0.51 basic per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}